---
layout: default
title: Aluminum Oxide American Ginseng Anemone Pulsatilla
parent: 僅模型預測 (L5)
nav_order: 268
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide American Ginseng Anemone Pulsatilla
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: Evaluation Not Possible — Insufficient Data

## One-Sentence Summary

This submission contains a 25-ingredient homeopathic/botanical complex (including Arnica montana, Echinacea, American Ginseng, Arsenic trioxide in homeopathic dilution, and others) with no established INN identity, no regulatory authorization in the United States, and no original approved indication on record.
The TxGNN model returned **zero predicted indications**, as the drug could not be mapped to any single DrugBank entity.
A meaningful drug repurposing evaluation **cannot be completed** with the currently available data.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no approvals on record) |
| Predicted New Indication | None — TxGNN returned 0 candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — no actual studies linked to this mixture as a whole) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why a Prediction Was Not Generated

The mixture contains 25 heterogeneous active substances spanning conventional inorganic compounds (aluminum oxide, iodine, sodium chloride, potassium carbonate), heavy metal-based homeopathic agents (arsenic trioxide, silver nitrate, phosphorus), botanical roots and extracts (Echinacea, American ginseng, Arnica montana, Bryonia alba, Gelsemium sempervirens, Chelidonium majus, etc.), and animal-derived material (Lytta vesicatoria). Several of these — such as Conium maculatum and Strychnos nux-vomica — are classical homeopathic preparations used at ultra-dilute concentrations far below pharmacological thresholds.

The TxGNN knowledge graph operates at the level of a single drug entity with a DrugBank ID and a defined mechanism of action. This mixture could not be resolved to any single DrugBank entry (`drugbank_id: null`), which means no node exists in the knowledge graph to run repurposing traversal from. Without a graph anchor, the model produces no output — this is expected behaviour, not a model failure.

There is also no shared mechanism of action across the 25 components that could be analysed as a unified pharmacological class. Any repurposing hypothesis would need to be built ingredient-by-ingredient, which requires individual DrugBank entries and indication records for each component.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this mixture as a unified entity.

---

## Literature Evidence

Currently no related literature available linking this exact combination to a specific repurposing target.

---

## US Market Information

This product has no US NDA, ANDA, or OTC monograph approval on record in the dataset queried. No authorization table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers**: Several individual components carry meaningful toxicity signals at pharmacological doses — particularly arsenic trioxide (cardiotoxicity, QT prolongation), Conium maculatum (nicotinic receptor toxicity), Strychnos nux-vomica (strychnine, CNS excitotoxicity), and Lytta vesicatoria (cantharidin, nephrotoxicity). If any future formulation contains these above homeopathic dilution levels, a dedicated safety review is mandatory before any clinical use evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack contains no approved indication, no DrugBank mapping, no TxGNN predictions, and no safety data — the minimum inputs required for a repurposing evaluation are absent. Proceeding would generate conclusions without an evidence base.

**To proceed, the following is needed:**

- **Identity clarification**: Confirm whether this is a registered homeopathic product, a compounded formula, or a research mixture — obtain the product's brand name and any existing monograph
- **DrugBank mapping**: Either identify the lead active ingredient (e.g., arsenic trioxide if this is a dilute formulation) and map it individually, or obtain separate DrugBank IDs for each component
- **Regulatory status**: Determine if any individual ingredient in this mixture is independently approved for a specific indication — repurposing analysis can then be run per ingredient
- **Formulation-level safety document**: Obtain or reconstruct a full package insert to complete the blocking DG001 data gap
- **TxGNN re-query**: Once at least one DrugBank ID is available, re-submit as individual drug entries rather than as a concatenated multi-ingredient string
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

